Crohn’s Disease vs. Ulcerative Colitis: Segmenting the Inflammatory Bowel Disease Market for 2025–2032
Inflammatory Bowel Disease (IBD), a group of chronic conditions affecting the gastrointestinal tract, has been steadily shaping the global healthcare landscape. Crohn’s disease and ulcerative colitis, the two main types of IBD, have seen a surge in prevalence over the past few decades. This rise in cases is fueling the demand for more effective and innovative therapies. The inflammatory bowel disease market is expected to experience significant growth in the coming years as research and technological advancements lead to better management strategies and improved patient outcomes. According to persistence market research, the global inflammatory bowel disease market size is likely to be valued at US$ 25.5 Bn in 2025 and is estimated to reach US$ 36.4 Bn by 2032, growing at a CAGR of 5.2% during the forecast period 2025–2032. This growth is primarily attributed to the increasing incidence of IBD, the evolution of personalized medicine, and advances in treatment options. Key Drive...